Background and Need for Legislation
Biomedical research frequently employs animal models to
investigate biological processes, analyze diseases, and explore
potential therapies. In drug development, researchers have
traditionally tested safety of drugs in animals before starting
human clinical trials.\1\ While animal studies can reliably
predict some human responses and side effects,\2\ they may not
provide a comprehensive prediction of how humans might react to
medications or of the overall effects a drug could have on
human health. This is especially true regarding the ability of
animal models to predict the effectiveness of drugs for
conditions such as cancer, Alzheimer's, and inflammatory
diseases.\3\
---------------------------------------------------------------------------
\1\Food and Drug Administration (FDA), Reducing Animal Testing in
Nonclinical Studies: Year One Progress and the Path Forward at 2 (Apr.
20, 2026), https://www.fda.gov/media/191986/download?attachment.
\2\Michael C.J. Chang & Franziska B. Grieder, LAB ANIMAL, The
continued importance of animals in biomedical research (2024).
\3\FDA, Roadmap to Reducing Animal Testing in Preclinical Safety
Studies at 1 (April 10, 2025), https://www.fda.gov/media/186092/
download?attachment.
---------------------------------------------------------------------------
Due to ethical concerns and the scientific limitations of
animal testing in research, the scientific community has
increasingly considered development and use of new approach
methodologies (NAMs), which are novel tools to assess drug
safety, efficacy, and pharmacology without traditional animal
models.\4\ According to the Food and Drug Administration (FDA),
NAMs encompass a variety of testing methods and strategies,
including in vitro and human-based systems, in silico and
computational modeling tools, as well as other emerging
technologies and innovative platforms.\5\
---------------------------------------------------------------------------
\4\FDA, New Approach Methodologies (NAMs) (Apr. 20, 2026), https://
www.fda.gov/science-
research/science-and-research-special-topics/new-approach-
methodologies-nams#activities.
\5\FDA, supra note 2 at 1-4.
---------------------------------------------------------------------------
Congress has directed federal agencies to seek alternatives
to animal testing for safety and efficacy assessments when
scientifically justified.\6\ The existing federal policy
framework reflects decades of efforts to strike the right
balance between animal welfare concerns and the value of animal
tests in scientific research.\7\
---------------------------------------------------------------------------
\6\Eleni G. Bickell & Kavya Sekar, CONG. RSCH. SERV. (CRS),
IF120002, Animal Use in Federal Biomedical Research: A Policy Overview
(2023).
\7\Id.
---------------------------------------------------------------------------
In 2022, Congress passed the FDA Modernization Act 2.0, as
part of the Consolidated Appropriations Act of 2023.\8\ This
legislation amended the Federal Food, Drug, and Cosmetic Act
(FD&C Act) to authorize the use of non-animal alternatives to
support investigational new drug (IND) applications and removed
a requirement to include animal studies in biosimilar biologic
license applications (BLAs).\9\ However, FDA has not yet made
conforming changes to the relevant regulations to implement the
changes made under that Act.
---------------------------------------------------------------------------
\8\Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, 136
Stat. 4459 (2022).
\9\FDA, supra note 2 at 1.
---------------------------------------------------------------------------
H.R. 2821, the FDA Modernization Act 3.0, would require
HHS, the agency under which the FDA falls, to publish an
interim final rule to amend certain regulations to replace
references of ``animal'' tests, data, studies, models, and
research with references to ``nonclinical'' tests, data,
studies, models, and research.
The FDA Modernization Act 3.0 was first introduced in
February 2024 during the 118th Congress. It was reintroduced in
April 2025, during the 119th Congress, as H.R. 2821. The FDA
also released its ``Roadmap to Reduce Animal Testing'' in April
2025 and outlined its plan for reducing preclinical safety
animal testing by using validated NAMs.\10\
---------------------------------------------------------------------------
\10\Press Release, FDA, FDA Announces Plan to Phase Out Animal
Testing Requirement for Monoclonal Antibodies and Other Drugs (Apr. 10,
2025), https://www.fda.gov/news-events/press-announcements/fda-
announces-plan-phase-out-animal-testing-requirement-monoclonal-
antibodies-and-other-drugs.
---------------------------------------------------------------------------
Committee Action
On July 16, 2025, the Subcommittee on Health held a
legislative hearing on H.R. 2821. The Subcommittee received
testimony from:
Jacqueline Corrigan-Curay, JD, MD, Acting
Director for Center for Drug Evaluation and Research
(CDER), U.S. Food and Drug Administration;
Candice Chen, MD, MPH, Acting Associate
Administrator for Health Workforce, U.S. Health
Resources and Services Administration; and
Tom Morris, MPA, Associate Administrator for
Rural Health Policy, U.S. Health Resources and Services
Administration.
On May 13, 2026, the Subcommittee on Health met in open
markup session and forwarded H.R. 2821, without amendment, to
the full Committee by a voice vote.
On May 21, 2026, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 2821, without
amendment, favorably reported to the House by a record vote of
44 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to require
the Secretary to publish an interim final rule to amend certain
regulations to replace references of animal tests, data,
studies, models, and research with nonclinical references to
these items.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 2821 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 2821:
On July 16, 2025, the Subcommittee on Health
held a legislative hearing on H.R. 2821. The title of
the hearing was ``Legislative Proposals to Maintain and
Improve the Public Health Workforce, Rural Health, and
Over-the-Counter Medicines.'' The Subcommittee received
testimony from:
Jacqueline Corrigan-Curay, JD,
MD, Acting Director for Center for Drug
Evaluation and Research (CDER), U.S. Food and
Drug Administration;
Candice Chen, MD, MPH, Acting
Associate Administrator for Health Workforce,
U.S. Health Resources and Services
Administration; and
Tom Morris, MPA, Associate
Administrator for Rural Health Policy, U.S.
Health Resources and Services Administration.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 2821 contains no earmarks, limited
tax benefits, or limited tariff benefits
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``FDA Modernization Act
3.0.''
Section 2. Regulations on nonclinical testing methods
Section 2 requires the Secretary to publish an interim
final rule no later than one year after the enactment of H.R.
2821 to amend certain sections (listed in the bill text) of
title 21 of the Code of Federal Regulations, replacing
references to ``animal'' tests, data, studies, models, and
research with references to ``nonclinical'' tests, data,
studies, models, and research. The interim final rule must also
add the definition of ``nonclinical test,'' located in section
505(z) of the FD&C Act, to specific sections (also listed) of
title 21 of the Code of Federal Regulations.
Additionally, section 2 specifies that the interim final
rule issued by HHS shall take effect immediately as an interim
final rule, without requiring the Secretary to demonstrate good
cause.
Finally, this section includes a technical amendment to
section 505 of the FD&C Act to designate the second subsection
(z), which relates to clinical trial diversity action plans, as
added by section 3601(a) of the Health Extenders, Improving
Access to Medicare, Medicaid, and CHIP, and Strengthening
Public Health Act of 2022, as subsection (aa).
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
FEDERAL FOOD, DRUG, AND COSMETIC ACT
* * * * * * *
CHAPTER V--DRUGS AND DEVICES
Subchapter A--Drugs and Devices
* * * * * * *
new drugs
Sec. 505. (a) No person shall introduce or deliver for
introduction into interstate commerce any new drug, unless an
approval of an application filed pursuant to subsection (b) or
(j) is effective with respect to such drug.
(b)
(b)(1)(A) Any person may file with the Secretary an
application with respect to any drug subject to the provisions
of subsection (a). Such persons shall submit to the Secretary
as part of the application--
(i) full reports of investigations which have been
made to show whether such drug is safe for use and
whether such drug is effective in use;
(ii) a full list of the articles used as components
of such drug;
(iii) a full statement of the composition of such
drug;
(iv) a full description of the methods used in, and
the facilities and controls used for, the manufacture,
processing, and packing of such drug;
(v) such samples of such drug and of the articles
used as components thereof as the Secretary may
require;
(vi) specimens of the labeling proposed to be used
for such drug;
(vii) any assessments required under section 505B;
and
(viii) the patent number and expiration date of each
patent for which a claim of patent infringement could
reasonably be asserted if a person not licensed by the
owner of the patent engaged in the manufacture, use, or
sale of the drug, and that--
(I) claims the drug for which the applicant
submitted the application and is a drug
substance (active ingredient) patent or a drug
product (formulation or composition) patent; or
(II) claims a method of using such drug for
which approval is sought or has been granted in
the application.
(B) If an application is filed under this subsection for a
drug, and a patent of the type described in subparagraph
(A)(viii) is issued after the filing date but before approval
of the application, the applicant shall amend the application
to include the patent number and expiration date.
(2) An application submitted under paragraph (1) for a drug
for which the investigations described in clause (A) of such
paragraph and relied upon by the applicant for approval of the
application were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference or
use from the person by or for whom the investigations were
conducted shall also include--
(A) a certification, in the opinion of the applicant
and to the best of his knowledge, with respect to each
patent which claims the drug for which such
investigations were conducted or which claims a use for
such drug for which the applicant is seeking approval
under this subsection and for which information is
required to be filed under paragraph (1) or subsection
(c)--
(i) that such patent information has not been
filed,
(ii) that such patent has expired,
(iii) of the date on which such patent will
expire, or
(iv) that such patent is invalid or will not
be infringed by the manufacture, use, or sale
of the new drug for which the application is
submitted; and
(B) if with respect to the drug for which
investigations described in paragraph (1)(A) were
conducted information was filed under paragraph (1) or
subsection (c) for a method of use patent which does
not claim a use for which the applicant is seeking
approval under this subsection, a statement that the
method of use patent does not claim such a use.
(3) Notice of opinion that patent is invalid or will not be
infringed.--
(A) Agreement to give notice.--An applicant that
makes a certification described in paragraph (2)(A)(iv)
shall include in the application a statement that the
applicant will give notice as required by this
paragraph.
(B) Timing of notice.--An applicant that makes a
certification described in paragraph (2)(A)(iv) shall
give notice as required under this paragraph--
(i) if the certification is in the
application, not later than 20 days after the
date of the postmark on the notice with which
the Secretary informs the applicant that the
application has been filed; or
(ii) if the certification is in an amendment
or supplement to the application, at the time
at which the applicant submits the amendment or
supplement, regardless of whether the applicant
has already given notice with respect to
another such certification contained in the
application or in an amendment or supplement to
the application.
(C) Recipients of notice.--An applicant required
under this paragraph to give notice shall give notice
to--
(i) each owner of the patent that is the
subject of the certification (or a
representative of the owner designated to
receive such a notice); and
(ii) the holder of the approved application
under this subsection for the drug that is
claimed by the patent or a use of which is
claimed by the patent (or a representative of
the holder designated to receive such a
notice).
(D) Contents of notice.--A notice required under this
paragraph shall--
(i) state that an application that contains
data from bioavailability or bioequivalence
studies has been submitted under this
subsection for the drug with respect to which
the certification is made to obtain approval to
engage in the commercial manufacture, use, or
sale of the drug before the expiration of the
patent referred to in the certification; and
(ii) include a detailed statement of the
factual and legal basis of the opinion of the
applicant that the patent is invalid or will
not be infringed.
(4)(A) An applicant may not amend or supplement an
application referred to in paragraph (2) to seek approval of a
drug that is a different drug than the drug identified in the
application as submitted to the Secretary.
(B) With respect to the drug for which such an application is
submitted, nothing in this subsection or subsection (c)(3)
prohibits an applicant from amending or supplementing the
application to seek approval of a different strength.
(5)(A) The Secretary shall issue guidance for the individuals
who review applications submitted under paragraph (1) or under
section 351 of the Public Health Service Act, which shall
relate to promptness in conducting the review, technical
excellence, lack of bias and conflict of interest, and
knowledge of regulatory and scientific standards, and which
shall apply equally to all individuals who review such
applications.
(B) The Secretary shall meet with a sponsor of an
investigation or an applicant for approval for a drug under
this subsection or section 351 of the Public Health Service Act
if the sponsor or applicant makes a reasonable written request
for a meeting for the purpose of reaching agreement on the
design and size--
(i)(I) of clinical trials intended to form the
primary basis of an effectiveness claim; or
(II) in the case where human efficacy studies are not
ethical or feasible, of animal and any associated
clinical trials which, in combination, are intended to
form the primary basis of an effectiveness claim; or
(ii) with respect to an application for approval of a
biological product under section 351(k) of the Public
Health Service Act, of any necessary clinical study or
studies.
The sponsor or applicant shall provide information necessary
for discussion and agreement on the design and size of the
clinical trials. Minutes of any such meeting shall be prepared
by the Secretary and made available to the sponsor or applicant
upon request.
(C) Any agreement regarding the parameters of the design and
size of clinical trials of a new drug under this paragraph that
is reached between the Secretary and a sponsor or applicant
shall be reduced to writing and made part of the administrative
record by the Secretary. Such agreement shall not be changed
after the testing begins, except--
(i) with the written agreement of the sponsor or
applicant; or
(ii) pursuant to a decision, made in accordance with
subparagraph (D) by the director of the reviewing
division, that a substantial scientific issue essential
to determining the safety or effectiveness of the drug
has been identified after the testing has begun.
(D) A decision under subparagraph (C)(ii) by the director
shall be in writing and the Secretary shall provide to the
sponsor or applicant an opportunity for a meeting at which the
director and the sponsor or applicant will be present and at
which the director will document the scientific issue involved.
(E) The written decisions of the reviewing division shall be
binding upon, and may not directly or indirectly be changed by,
the field or compliance division personnel unless such field or
compliance division personnel demonstrate to the reviewing
division why such decision should be modified.
(F) No action by the reviewing division may be delayed
because of the unavailability of information from or action by
field personnel unless the reviewing division determines that a
delay is necessary to assure the marketing of a safe and
effective drug.
(G) For purposes of this paragraph, the reviewing division is
the division responsible for the review of an application for
approval of a drug under this subsection or section 351 of the
Public Health Service Act (including all scientific and medical
matters, chemistry, manufacturing, and controls).
(6) An application submitted under this subsection
shall be accompanied by the certification required
under section 402(j)(5)(B) of the Public Health Service
Act. Such certification shall not be considered an
element of such application.
(7) Rx-to-nonprescription switches.--
(A) Meetings.--Any person planning to submit
an application for an Rx-to-nonprescription
switch may submit to the Secretary a written
request for a meeting, for purposes of
developing a plan for such application that
addresses the potential risks to public health
of such switch and the evidence necessary to
support such application, including the design
of any necessary studies, and the format and
content of the planned application. The
Secretary may grant such a meeting, as
appropriate, consistent with established
procedures for granting meetings with, and
providing written responses to, applications
under this section. Each such meeting shall be
documented in meeting minutes.
(B) Guidance.--
(i) In general.--Not later than 18
months after the date of enactment of
this paragraph, the Secretary shall
issue guidance to increase the clarity
and predictability of the process and
standards for approval of applications
for nonprescription drugs under this
section, including in the case of
applications for an Rx-to-
nonprescription switch, especially with
respect to prescription drugs with
well-established safety profiles for
which an applicant may seek approval
for nonprescription use.
(ii) Contents.--The guidance under
clause (i) shall--
(I) describe how published
reports in medical literature,
any previous finding of safety
or effectiveness for the drug
under this section, the results
of significant human experience
with the drug, unpublished
studies and other data, and
other sources of information
may be used to support an
application for a
nonprescription drug, including
in the context of an
application for an Rx-to-
nonprescription switch;
(II) set forth procedures for
sponsors to request meetings
described in subparagraph (A)
and document the
recommendations made in such
meetings;
(III) describe evidentiary
expectations to support
approval of an application for
a nonprescription drug,
i